Boosting the product line

Assay Designs enters strategic agreement with Abnova Corp.

Register for free to listen to this article
Listen with Speechify
ANN ARBOR, Mich.—In a move that increases its product line by roughly two-thirds, Assay Designs Inc., a provider of immunoassay kits, antibodies and reagents, recently announced a strategic agreement with Abnova Corp. of Taiwan.
The agreement allows Assay Designs to distribute approximately 3,200 of Abnova's highly characterized monoclonal antibodies to its U.S. and Canadian customers. That expands Assay Designs' current product portfolio to include more than 5,300 reagents for such research areas as cell signaling, cellular stress, neuroscience and inflammation.

"Abnova's capacity to develop and produce antibodies is very complementary to our current antibody and immunoassay businesses, and affords our customer base easy access to their most highly characterized monoclonals for applications such as ELISA, immunohistochemistry, and immunofluorescence as well as western blotting," says Dan Calvo, CEO of Assay Designs.

According to Wilbur Huang, CEO of Abnova, "Assay Designs' expertise in immunoassay and system development highly complements Abnova's capability in industrial-scale antibody manufacturing based on 'one gene one antibody' translation of the human genome."

An attraction for joining forces with Abnova is that it seeks to be—and seems quite likely to become—the world's largest antibody distributor, notes Dana Haley-Vicente, senior product manager at Assay Designs. One piece of evidence to support that is the company's capacity of generating 500 mouse monoclonal antibodies and 500 rabbit polyclonal antibodies per month.

Another selling point was the fact many Abnova products are within Assay Designs' major research areas, such as cellular stress, and going with a different company might have resulted in a partner with less crossover with Assay Design's customer segments.
Assay Designs intends to enter additional partnerships with Abnova for other products it offers and also would like to enter co-development agreements with Abnova, Haley-Vicente says. DDN

Published In:

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue